Iron Replacement Therapy
Customize your policy alerts
Sign up for scrippshealthplan Policy SHPS 1600 alerts
Get alerted when Policy SHPS 1600 changes without checking for updates manually.
Monitor payer policy activity
Clinical guideline governing prior authorization and utilization management for IV iron replacement therapy for Scripps Health Plan Services members (Medicare Advantage+ and Commercial). Applies to providers requesting IV iron products listed in the policy.
No material clinical or coverage changes in this revision.
Coverage Criteria for IV Iron Replacement Therapy
Initial Coverage — Iron Deficiency or Iron Deficiency Anemia
Covered when ALL of the following are met for Iron Deficiency or Iron Deficiency Anemia
Iron Deficiency/Anemia criteria
- Age is consistent with FDA labeled indication
- Indication: Patient has non-dialysis dependent chronic kidney disease OR inadequate response, intolerable side effect, or intolerance to oral iron supplementation
- IV product response/contraindication: Inadequate response or intolerable side effect to preferred generic IV iron products (iron sucrose and ferumoxytol) OR contraindication to both preferred generic iron products (iron sucrose and ferumoxytol)
Injectafer coverage for heart failure-related iron deficiency
Covered when ALL of the following are met for Iron Deficiency with Heart Failure (Injectafer only)
Injectafer (ferric carboxymaltose) in heart failure
- Age is consistent with FDA labeled indication
- Heart failure class: Patient has New York Heart Association (NYHA) class II or III heart failure
- IV product response/contraindication: Inadequate response or intolerable side effect to all generic IV iron products (ferric gluconate, iron sucrose, ferumoxytol) OR contraindication to all generic IV iron products
Age must be consistent with the FDA labeled indication for the requested intravenous iron product. The policy explicitly requires that the member’s age align with the manufacturer’s approved age range as a condition of meeting medical necessity for IV iron therapy for iron deficiency or iron deficiency anemia. Agents used outside their FDA age indication are not supported by these criteria and therefore would not meet coverage requirements.
Use of IV iron that does not satisfy the stated medical necessity criteria may be considered not medically necessary. Examples include failure to meet the required clinical conditions (for example, absence of non-dialysis CKD or no documentation of inadequate response/intolerance to oral iron when that criterion is applicable) or lack of required prior trials of preferred agents (e.g., no documented inadequate response or intolerance to preferred generic IV iron products such as iron sucrose and ferumoxytol). The UM department will apply these criteria during prior authorization review and may deny coverage when criteria are not met.
Referenced Codes and Age/Indication
Provider Requirements and Authorization Workflow
Prior authorization required for listed IV iron agents
Prior authorization/review is required through SHPS Utilization Management and requests will be evaluated using the policy criteria. The policy specifically references Injectafer (J1439), Venofer (J1756), Monoferric (J1437), Infed (J1750), and Feraheme (Q0138/Q0139) as IV iron replacements covered by this guideline.
- Submit prior authorization to SHPS Utilization Management for any listed IV iron product.
- SHPS UM will apply the medical necessity criteria in this policy when reviewing requests.
Step-therapy: try preferred generic IV irons first
A step-therapy preference requires trial of preferred generic IV iron products (iron sucrose and ferumoxytol, and where listed ferric gluconate) or documentation of contraindication/intolerance before approval of non-preferred agents such as Injectafer.
- Providers should document inadequate response or intolerable side effects to preferred generics (iron sucrose, ferumoxytol, ferric gluconate) when requesting non-preferred agents.
- If both (or all) preferred generic agents are contraindicated, document the contraindications.
Documentation to support UM review
Utilization Management staff will triage which criteria to utilize per standard work and apply this guideline for determination when no other guideline exists; providers should submit documentation that supports the specific criteria being claimed (e.g., age consistent with FDA labeling, CKD status, NYHA class, trials/intolerance of oral or generic IV iron).
- Include patient age consistent with FDA labeled indication.
- Provide documentation of CKD status or NYHA class II/III if applicable.
- Provide records showing inadequate response or intolerance to oral iron and to preferred generic IV iron products, or documented contraindications.
Denial risk if criteria or guideline requirements are not met
Denial may occur if the UM department determines that the policy criteria or other applicable guidelines (SHPS criteria, CMS NCD/LCD, MCG, or other established guidelines) are not met when processing referrals for IV iron therapy.
- Common denial triggers include lack of documentation of age consistent with FDA labeling, missing evidence of CKD or NYHA class when required, or absence of documented trials/intolerance/contraindications to preferred agents.
- Requests for IV iron that do not meet the stated medical necessity criteria are considered not medically necessary per UM determination.
Clinical Background
Iron deficiency anemia (IDA) results from insufficient body iron stores and commonly presents with symptoms such as fatigue, dyspnea, and chest pain; severe or prolonged iron deficiency can contribute to heart failure or developmental delay. Common causes include gastrointestinal blood loss, chronic kidney disease, malabsorption (e.g., celiac disease), frequent blood donation, and chemotherapy. Clinical guidelines support a trial of oral iron for many patients before IV iron, with IV iron indicated in particular settings such as chronic kidney disease or when oral iron is not tolerated or not effective.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.